LINC00460 knockdown sensitizes cervical cancer to cisplatin by downregulating TGFBI
Chemical Biology and Drug Design
DECEMBER 28, 2023
LINC00460 knockdown contributed to DDP sensitivity of cervical cancer by regulating TGFBI, providing a novel mechanism underlying the acquisition of DDP sensitivity. Abstract The acquired resistance of cancer to cisplatin (DDP) limits the efficacy of chemotherapy. The prognostic value of long noncoding RNA (lncRNA) LINC00460 has been reported in cervical cancer.
Let's personalize your content